RET S409Y种系突变与相关的甲状腺髓样癌
本研究报道了携带RET原癌基因第6外显子种系S409Y变异的甲状腺髓样癌(MTC)家系。通过靶向测序诊断4例看似散发的MTC先证者,并对27名亲属进行临床和遗传评估。31名参与者中15人携带RET S409Y变异,其中6人患孤立性MTC,3人降钙素水平升高。体外实验显示S409Y变异可增强RET酪氨酸磷酸化及AKT、ERK通路活性,促进细胞增殖,但作用弱于C618Y和C634Y突变。结论认为S409Y可能致病,外显率低于C618Y和C634Y。
要点
- RET S409Y种系变异可能致病,与MTC相关但外显率较低
- 携带者中6/15出现孤立性MTC,部分已有淋巴结或远处转移
- S409Y变异激活RET下游AKT/ERK通路,但活性弱于C618Y/C634Y
核心结论
- 新型种系RET S409Y变异可能致病,与MTC相关且外显率低于C618Y和C634Y突变。
- S409Y携带者应采取个体化管理,并对其高危家属进行评估。
研究设计与样本
- 研究通过靶向测序诊断4例携带种系RET S409Y(c.1226 C>A)变异的看似散发性MTC先证者。
- 对27名亲属进行临床和遗传评估和/或甲状腺手术,共31名参与者。
- 进行计算机模拟分析和体外实验验证S409Y变异的潜在致癌活性。
主要发现
- 31名参与者中15人携带RET S409Y变异。
- 6例携带者表现为孤立性MTC(平均年龄50.2岁,范围41-75岁),其中3例有颈部淋巴结转移,2例有肝或肺远处转移。
- 剩余9例携带者中,3例(平均年龄56岁,范围41-76岁)血清钙刺激降钙素(sCtn)升高或同时血清降钙素(Ctn)边缘升高,另6例(平均年龄37.5岁,范围14-52岁)Ctn/sCtn水平典型(p < 0.05)。
- 15例携带者均无嗜铬细胞瘤、甲状旁腺功能亢进或先天性巨结肠症的临床证据。
- 计算机模拟分析显示S409Y为「可能有害」突变,可能影响RET蛋白结构域界面;体外实验显示S409Y突变体RET酪氨酸905磷酸化水平相对高于野生型,转染HEK 293细胞后AKT、ERK通路磷酸化活性增强且细胞增殖增加,但程度低于RET C618Y和C634Y突变。
关键数值与推荐
- RET S409Y变异定位于第6外显子(c.1226 C>A)。
- 携带者中孤立性MTC的平均年龄50.2岁(范围41-75岁)。
- Ctn/sCtn升高组与典型组年龄差异p < 0.05。
临床怎么用
- 对看似散发性MTC患者应考虑RET种系基因检测,包括第6外显子等非常见突变区域。
- 检出RET S409Y变异者应进行个体化管理和长期监测,并对其高危家属进行遗传评估。
局限性
- 研究样本量较小(31名参与者,4个家系),需更大样本验证。
- S409Y与2型多内分泌腺瘤病特异性肿瘤的相关性仍需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Inherited medullary thyroid carcinoma (MTC) is primarily caused by RET mutations that are commonly localized in exons 5, 8, 10, 11, and 13-16. In this study, we report pedigrees for individuals with MTC that harbor a germline S409Y variant within exon 6 of the RET proto-oncogene. Methods: Targeted sequencing was used to diagnose four apparently sporadic MTC index cases carrying the germline RET S409Y (c.1226 C>A) variant. Subsequently, 27 relatives of these individuals underwent clinical and genetic assessments and/or thyroid surgery. Furthermore, in silico analyses and in vitro assays were performed to predict or verify the potential oncogenic activity of the S409Y variant. Results: Overall, 15 of 31 participants were found to carry the RET S409Y variant. Of these, 6 presented with isolated MTC (mean age 50.2 years; range 41-75 years), of which 3 presented with neck lymph node metastases and 2 presented with distant liver or lung metastases. Among the remaining 9 carriers, 3 (mean age 56 years; range 41-76 years) had elevated serum calcium-stimulated calcitonin (sCtn) or concurrent marginally elevated serum calcitonin (Ctn) levels, whereas the other 6 (mean age 37.5 years; range 14-52 years) exhibited typical Ctn/sCtn levels (p < 0.05). None of the 15 carriers in these 4 families presented clinical evidence of pheochromocytoma, hyperparathyroidism, or Hirschsprung's disease. In silico analyses revealed that S409Y was a "possibly damaging" mutation that could affect the RET protein inter-domain interface. An in vitro assay revealed that the phosphorylation level of RET tyrosine 905 was relatively higher in the RET S409Y mutant than in wild-type (WT) RET. Moreover, transfection of HEK 293 cells with S409Y enhanced the phosphorylation activity of AKT, ERK pathways, and it increased cell proliferation compared with WT RET, but to a lesser degree than that for the RET C618Y and C634Y mutations. Conclusions: This study demonstrates that the novel germline RET S409Y variant is likely pathogenic and is associated with lower penetrance of MTC than that for the C618Y and C634Y mutations. Individuals with S409Y should be managed using a personalized approach, and additionally, "at-risk" family members should be evaluated. Additional studies are needed to elucidate the correlation between the S409Y mutation and multiple endocrine neoplasia type 2-specific tumors.
引用
- Qi XP, Jin BY, Li PF, et al. RET S409Y Germline Mutation and Associated Medullary Thyroid Carcinoma. Thyroid. 2019. PMID: 31364476. doi:10.1089/thy.2018.0385
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。